Gao Yanan, Mi Liangyu, Xu Ke
Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
Department of Rheumatology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
Inflamm Res. 2025 Jun 30;74(1):93. doi: 10.1007/s00011-025-02061-0.
Autoimmune diseases (AIDs) are a spectrum of chronic conditions characterized by abnormal immune responses directed against the body's own tissues. Current therapeutic strategies still rely on broad-spectrum immunosuppression, which often produces severe adverse effects and is ineffective in targeting comorbidities. The complement system, a key component of innate immunity, has been increasingly recognized for its role in the pathogenesis and progression of AIDs. This review aims to assess the diagnostic and therapeutic potential of targeting the complement system in AIDs.
A comprehensive literature review was conducted using the PubMed, Medscape, and ClinicalTrials.gov databases. The analysis included both original research and review articles, as well as data from ongoing and completed clinical trials focused on complement-targeted therapies.
Complement activation contributes to inflammation, tissue injury, and amplification of adaptive immunity in AIDs. Current and emerging complement-targeted therapies, including monoclonal antibodies and small-molecule inhibitors has shown promising preliminary outcomes in reducing disease activity with fewer adverse effects.
Targeting the complement system represents a promising and more precise strategy for the treatment of AIDs. Ongoing clinical evaluation is essential to establish its long-term safety and efficacy, with the potential to significantly advance future therapeutic approaches.
自身免疫性疾病（AIDs）是一系列慢性疾病，其特征是针对机体自身组织的异常免疫反应。目前的治疗策略仍依赖于广谱免疫抑制，这往往会产生严重的不良反应，且对合并症无效。补体系统作为固有免疫的关键组成部分，其在AIDs发病机制和进展中的作用日益受到认可。本综述旨在评估靶向补体系统在AIDs中的诊断和治疗潜力。
使用PubMed、Medscape和ClinicalTrials.gov数据库进行全面的文献综述。分析包括原创研究和综述文章，以及来自正在进行和已完成的聚焦补体靶向治疗的临床试验数据。
补体激活在AIDs中促进炎症、组织损伤和适应性免疫的放大。当前及新兴的补体靶向治疗，包括单克隆抗体和小分子抑制剂，在降低疾病活动度方面已显示出有前景的初步结果，且不良反应较少。
靶向补体系统是一种有前景且更精准的AIDs治疗策略。正在进行的临床评估对于确定其长期安全性和有效性至关重要，有可能显著推进未来的治疗方法。
